Fate Therapeutics, Inc. (FATE): $86.19

0.23 (+0.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FATE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

Fate Therapeutics Inc (FATE) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Fate Therapeutics Inc.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
17 $145 $71 $111.71 $85.82 30.17%

The Trend in the Analyst Price Target


Over the past 124 days, FATE's average price target has gone down $1.94.

FATE reports an average of 12.65% for its upside potential over the past 13 months.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-07-17 17 145 71 111.71 78.54 42.23%
2021-06-04 17 145 71 111.00 72.79 52.49%
2021-04-19 17 135 88 113.65 79.65 42.69%
2021-04-17 17 135 88 113.65 81.17 40.01%
2021-03-15 17 135 88 113.65 92.77 22.51%
2021-03-13 17 135 88 113.65 93.99 20.92%
2021-01-13 16 118 30 81.75 113.29 -27.84%
2021-01-09 16 118 30 81.75 116.31 -29.71%
2021-01-02 16 118 30 78.88 90.93 -13.25%
2020-11-23 14 71 30 54.36 54.29 0.13%
2020-11-20 13 71 30 53.54 52.65 1.69%
2020-11-14 14 71 30 52.57 50.51 4.08%
2020-10-26 16 60 29 42.12 46.90 -10.19%
2020-09-07 16 59 29 39.50 31.11 26.97%
2020-08-22 16 59 29 39.62 36.12 9.69%
2020-08-12 16 59 29 39.62 34.11 16.15%
2020-08-06 16 59 29 38.94 33.42 16.52%
2020-06-16 16 59 29 38.81 NA NA%
2020-06-16 17 59 29 39.00 NA NA%
2020-06-08 17 59 29 39.00 NA NA%

FATE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.44 6 7 4 0 0 17

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • Fate Therapeutics Inc's number of analysts covering the stock is higher than 89.56% of all US stocks.
  • The average analyst price target of FATE is higher than 93.58% of Pharmaceutical Products stocks.
  • The variance in analysts' estimates of FATE is lower than 13.47% of stocks in the mid market cap category.
  • FATE has a greater upside potential (average analyst target price relative to current price) than 19.97% of Pharmaceutical Products stocks.

In the Pharmaceutical Products industry, APLS, BMY and BMRN are the three stocks most similar to Fate Therapeutics Inc regarding the price target and analyst recommendation information presented here.

Is FATE a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6489 seconds.